Molly Mathew
Publications by Molly Mathew
3 publications found • Active 2013-2016
2016
1 publicationSynthesis and Antimicrobial Evaluation of some 2-Azetidinone derivatives
A new series of azetidinone derivatives have been synthesized due to the growing resistance of bacteria towards the â-lactam antibiotics. In our present study Oxadiazole is synthesized from semicarbazide is on condensation with substituted aldehyde to form Schiff base. The schiff bases are cyclized with chloroacetylchloride in triethylamine to yield the corresponding 2-azetidinones. Structures of synthesized compounds are confirmed by physical & spectral analysis. The compounds have screened for antimicrobial activity.
2014
1 publicationPreliminary screening of anaphyllum wightii schott tubers for anti-inflammatory and antioxidant activity
To evaluate the preliminary phytochemical, antioxidant and anti-inflammatory activity of77 Anaphyllum wightii Schott. Bovine Serum Albumin denaturation inhibition assay was used for the evaluation of in-vitro anti-inflammatory activity and DPPH. Free radical scavenging and super oxide scavenging assays were used to assess the antioxidant activity of chloroform and aqueous extracts of the tubers of Anaphyllum wightii Schott. In anti-denaturation study, it was observed that chloroform extract showed greater percentage of inhibition of bovine serum albumin denaturation ie 49.2% whereas aqueous extract showed 38.4% at the 400µg/ml concentration respectively. In case of antioxidant screening also, chloroform extract showed better antioxidant power compared to aqueous extract dose dependently. Among the two extracts evaluated for anti-inflammatory and antioxidant activities chloroform extract of Anaphyllum wightii was found to possess significantly good anti-inflammatory and antioxidant activities and this can be attributed to the presence of alkaloids, saponins, flavonoids and phenolic compounds.
2013
1 publicationTransdermal Delivery of Felodipine from Eudragit film
Felodipine is an effective calcium channel blocker, mainly used in the treatment of hypertension and angina pectoris. To overcome the low oral bioavailability of felodipine, the present work was designed to develop transdermal therapeutic system for felodipine using the polymer blend of eudragit RL 100 (ERL) / RS 100 (ERS) by solvent casting method. Dibutyl phthalate (DBP) and oleic acid (OA) were used as plasticizer and permeation enhancer respectively. Incorporation of DBP improved the flexibility, folding endurance and handling properties of the films. Increasing the concentration of ERL, and the presence of plasticizer were found to increase the in vitro drug release of the films. The patches were also evaluated for ex vivo skin permeation using human cadaver skin. The presence of OA produced significant increase in the flux and permeability constant. The formulation with ERL: ERS ratio 4:1, 5% w/w OA as permeation enhancer and 20% w/w DBP as plasticizer showed the best results which exhibited the cumulative percentage of drug release of 75.73 ± 2.179 % and the cumulative amount of drug permeation across skin of 4321 ± 11.533 µg/cm2 in 24 hrs. Drug-excipient interaction studies were carried out using DSC and IR technique; films indicated no chemical interaction between drug and excipients. The results of the skin irritation studies showed no noticeable irritancy on rabbit skin indicating the skin compatibility of the drug as well as polymer. An attempt was made to develop the complete transdermal system of the drug by using backing membrane and release liner.
